180 Wealth Advisors’s Eupraxia Pharmaceuticals EPRX Stock Holding History

180 Wealth Advisors’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,500	Closed	-$33.3K	–	451
2024 Q4	$33.3K	Sell	10,500 -2,500	-19%	-$7.4K	0.01%	425
2024 Q3	$34.2K	Hold	13,000	–	–	0.01%	443
2024 Q2	$34.1K	Buy	+13,000	New	+$36.2K	0.01%	431

Other funds holding EPRX

Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

180 Wealth Advisors's EPRX Position: Q1 2025 in Review

180 Wealth Advisors sold out of Eupraxia Pharmaceuticals (EPRX) in Q1 2025, closing a stake of 10,500 shares — an estimated $33.3K sold.

180 Wealth Advisors first reported a position in EPRX in Q2 2024 and held it in 3 quarters. The position peaked at $34.2K in Q3 2024. 11 funds tracked by Wall St. Rank hold EPRX as of Q1 2025.

180 Wealth Advisors reported no remaining Eupraxia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
180 Wealth Advisors sold 10,500 Eupraxia Pharmaceuticals shares in Q1 2025, an estimated $33.3K.
180 Wealth Advisors first reported a position in Eupraxia Pharmaceuticals in Q2 2024 and held it in 3 quarters.
180 Wealth Advisors's Eupraxia Pharmaceuticals position peaked at $34.2K in Q3 2024.
11 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2025.

Based on 180 Wealth Advisors's 13F filing for Q1 2025, filed 9 Apr 2025.